ABSTRACT

The HFEA has licensed PGD for certain severe or life-threatening disorders at a limited number of clinics. The problems the HFEA had with PGD generally were partially attributable to the fact that it 'does not appear on the face of the legislation' per Suzi Leather, Chair of HFEA, quoted in House of Commons Select Committee Report. PGD and HLA had already been used for this purpose in Colorado in the USA in the Nash case. Another argument adduced by those who oppose 'saviour siblings', as was observed in CORE's arguments in the Hashmi case, is that by allowing this to happen we will step on to the slippery slope, The concern, more generally, of Francis Fukuyama, Our Posthuman Future: Consequences of the Biotechnology Revolution, New York, Farrar, Strauss and Giroux, 2002.